1
|
Tune T, Kooiker KB, Davis J, Daniel T, Moussavi-Harami F. Identifying Mechanisms and Therapeutic Targets in Muscle using Bayesian Parameter Estimation with Conditional Variational Autoencoders. BIORXIV : THE PREPRINT SERVER FOR BIOLOGY 2024:2024.05.08.593035. [PMID: 38766103 PMCID: PMC11100674 DOI: 10.1101/2024.05.08.593035] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/22/2024]
Abstract
Cardiomyopathies, often caused by mutations in genes encoding muscle proteins, are traditionally treated by phenotyping hearts and addressing symptoms post irreversible damage. With advancements in genotyping, early diagnosis is now possible, potentially preventing such damage. However, the intricate structure of muscle and its myriad proteins make treatment predictions challenging. Here we approach the problem of estimating therapeutic targets for a mutation in mouse muscle using a spatially explicit half sarcomere muscle model. We selected 9 rate parameters in our model linked to both small molecules and cardiomyopathy-causing mutations. We then randomly varied these rate parameters and simulated an isometric twitch for each combination to generate a large training dataset. We used this dataset to train a Conditional Variational Autoencoder (CVAE), a technique used in Bayesian parameter estimation. Given simulated or experimental isometric twitches, this machine learning model is able to then predict the set of rate parameters which are most likely to yield that result. We then predict the set of rate parameters associated with both control and the cardiac Troponin C (cTnC) I61Q variant in mouse trabeculae and model parameters that recover the abnormal I61Q cTnC twitches. SIGNIFICANCE Machine learning techniques have potential to accelerate discoveries in biologically complex systems. However, they require large data sets and can be challenging in high dimensional systems such as cardiac muscle. In this study, we combined experimental measures of cardiac muscle twitch forces with mechanistic simulations and a newly developed mixture of Bayesian inference with neural networks (in autoencoders) to solve the inverse problem of determining the underlying kinetics for observed force generation by cardiac muscle. The autoencoders are trained on millions of simulations spanning parameter spaces that correspond to the mechanochemistry of cardiac sarcomeres. We apply the trained model to experimental data in order to infer parameters that can explain a diseased twitch and ways to recover it.
Collapse
|
2
|
Ma W, del Rio CL, Qi L, Prodanovic M, Mijailovich S, Zambataro C, Gong H, Shimkunas R, Gollapudi S, Nag S, Irving TC. Myosin in autoinhibited off state(s), stabilized by mavacamten, can be recruited in response to inotropic interventions. Proc Natl Acad Sci U S A 2024; 121:e2314914121. [PMID: 38346202 PMCID: PMC10895252 DOI: 10.1073/pnas.2314914121] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/28/2023] [Accepted: 01/08/2024] [Indexed: 02/15/2024] Open
Abstract
Mavacamten is a FDA-approved small-molecule therapeutic designed to regulate cardiac function at the sarcomere level by selectively but reversibly inhibiting the enzymatic activity of myosin. It shifts myosin toward ordered off states close to the thick filament backbone. It remains elusive whether these myosin heads in the off state(s) can be recruited in response to physiological stimuli when required to boost cardiac output. We show that cardiac myosins stabilized in these off state(s) by mavacamten are recruitable by 1) Ca2+, 2) increased chronotropy [heart rate (HR)], 3) stretch, and 4) β-adrenergic (β-AR) stimulation, all known physiological inotropic interventions. At the molecular level, we show that Ca2+ increases myosin ATPase activity by shifting mavacamten-stabilized myosin heads from the inactive super-relaxed state to the active disordered relaxed state. At the myofilament level, both Ca2+ and passive lengthening can shift mavacamten-ordered off myosin heads from positions close to the thick filament backbone to disordered on states closer to the thin filaments. In isolated rat cardiomyocytes, increased stimulation rates enhanced shortening fraction in mavacamten-treated cells. This observation was confirmed in vivo in telemetered rats, where left-ventricular dP/dtmax, an index of inotropy, increased with HR in mavacamten-treated animals. Finally, we show that β-AR stimulation in vivo increases left-ventricular function and stroke volume in the setting of mavacamten. Our data demonstrate that the mavacamten-promoted off states of myosin in the thick filament are at least partially activable, thus preserving cardiac reserve mechanisms.
Collapse
Affiliation(s)
- Weikang Ma
- Biophysics Collaborative Access Team, Department of Biology, Illinois Institute of Technology, Chicago, IL60616
- Center for Synchrotron Radiation Research and Instrumentation, Illinois Institute of Technology, Chicago, IL60616
| | - Carlos L. del Rio
- Cardiovascular Drug Discovery, Bristol Myers Squibb, Brisbane, CA94005
- Cardiac Consulting, San Mateo, CA94010
| | - Lin Qi
- Department of Biology, Illinois Institute of Technology, Chicago, IL60616
| | - Momcilo Prodanovic
- Institute for Information Technologies, University of Kragujevac, Kragujevac34000, Serbia
- FilamenTech, Inc., Newtown, MA02458
| | | | | | - Henry Gong
- Department of Biology, Illinois Institute of Technology, Chicago, IL60616
| | - Rafael Shimkunas
- Cardiovascular Drug Discovery, Bristol Myers Squibb, Brisbane, CA94005
| | - Sampath Gollapudi
- Cardiovascular Drug Discovery, Bristol Myers Squibb, Brisbane, CA94005
| | - Suman Nag
- Cardiovascular Drug Discovery, Bristol Myers Squibb, Brisbane, CA94005
| | - Thomas C. Irving
- Biophysics Collaborative Access Team, Department of Biology, Illinois Institute of Technology, Chicago, IL60616
- Center for Synchrotron Radiation Research and Instrumentation, Illinois Institute of Technology, Chicago, IL60616
- Department of Biology, Illinois Institute of Technology, Chicago, IL60616
| |
Collapse
|
3
|
Ma W, del Rio CL, Qi L, Prodanovic M, Mijailovich S, Zambataro C, Gong H, Shimkunas R, Gollapudi S, Nag S, Irving TC. Myosin in autoinhibited off state(s), stabilized by mavacamten, can be recruited via inotropic effectors. BIORXIV : THE PREPRINT SERVER FOR BIOLOGY 2023:2023.04.10.536292. [PMID: 37090664 PMCID: PMC10120679 DOI: 10.1101/2023.04.10.536292] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 04/25/2023]
Abstract
Mavacamten is a novel, FDA-approved, small molecule therapeutic designed to regulate cardiac function by selectively but reversibly inhibiting the enzymatic activity of myosin. It shifts myosin towards ordered off states close to the thick filament backbone. It remains unresolved whether mavacamten permanently sequesters these myosin heads in the off state(s) or whether these heads can be recruited in response to physiological stimuli when required to boost cardiac output. We show that cardiac myosins stabilized in these off state(s) by mavacamten are recruitable by Ca2+, increased heart rate, stretch, and β-adrenergic (β-AR) stimulation, all known physiological inotropic effectors. At the molecular level, we show that, in presence of mavacamten, Ca2+ increases myosin ATPase activity by shifting myosin heads from the reserve super-relaxed (SRX) state to the active disordered relaxed (DRX) state. At the myofilament level, both Ca2+ and passive lengthening can shift ordered off myosin heads from positions close to the thick filament backbone to disordered on states closer to the thin filaments in the presence of mavacamten. In isolated rat cardiomyocytes, increased stimulation rates enhanced shortening fraction in mavacamten-treated cells. This observation was confirmed in vivo in telemetered rats, where left-ventricular dP/dtmax, an index of inotropy, increased with heart rate in mavacamten treated animals. Finally, we show that β-AR stimulation in vivo increases left-ventricular function and stroke volume in the setting of mavacamten. Our data demonstrate that the mavacamten-promoted off states of myosin in the thick filament are activable, at least partially, thus leading to preservation of cardiac reserve mechanisms.
Collapse
Affiliation(s)
- Weikang Ma
- BioCAT, Department of Biology, Illinois Institute of Technology, Chicago, IL, USA
| | - Carlos L. del Rio
- Cardiovascular Drug Discovery, Bristol Myers Squibb, Brisbane, CA 94005
| | - Lin Qi
- Department of Biology, Illinois Institute of Technology, Chicago, IL, USA
| | - Momcilo Prodanovic
- Institute for Information Technologies, University of Kragujevac, Kragujevac, Serbia
- FilamenTech, Inc., Newtown, MA 02458, USA
| | | | | | - Henry Gong
- Department of Biology, Illinois Institute of Technology, Chicago, IL, USA
| | - Rafael Shimkunas
- Cardiovascular Drug Discovery, Bristol Myers Squibb, Brisbane, CA 94005
| | - Sampath Gollapudi
- Cardiovascular Drug Discovery, Bristol Myers Squibb, Brisbane, CA 94005
| | - Suman Nag
- Cardiovascular Drug Discovery, Bristol Myers Squibb, Brisbane, CA 94005
| | - Thomas C. Irving
- BioCAT, Department of Biology, Illinois Institute of Technology, Chicago, IL, USA
| |
Collapse
|
4
|
Kooiker KB, Mohran S, Turner KL, Ma W, Martinson A, Flint G, Qi L, Gao C, Zheng Y, McMillen TS, Mandrycky C, Mahoney-Schaefer M, Freeman JC, Costales Arenas EG, Tu AY, Irving TC, Geeves MA, Tanner BC, Regnier M, Davis J, Moussavi-Harami F. Danicamtiv Increases Myosin Recruitment and Alters Cross-Bridge Cycling in Cardiac Muscle. Circ Res 2023; 133:430-443. [PMID: 37470183 PMCID: PMC10434831 DOI: 10.1161/circresaha.123.322629] [Citation(s) in RCA: 6] [Impact Index Per Article: 6.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 02/04/2023] [Revised: 07/10/2023] [Accepted: 07/13/2023] [Indexed: 07/21/2023]
Abstract
BACKGROUND Modulating myosin function is a novel therapeutic approach in patients with cardiomyopathy. Danicamtiv is a novel myosin activator with promising preclinical data that is currently in clinical trials. While it is known that danicamtiv increases force and cardiomyocyte contractility without affecting calcium levels, detailed mechanistic studies regarding its mode of action are lacking. METHODS Permeabilized porcine cardiac tissue and myofibrils were used for X-ray diffraction and mechanical measurements. A mouse model of genetic dilated cardiomyopathy was used to evaluate the ability of danicamtiv to correct the contractile deficit. RESULTS Danicamtiv increased force and calcium sensitivity via increasing the number of myosins in the ON state and slowing cross-bridge turnover. Our detailed analysis showed that inhibition of ADP release results in decreased cross-bridge turnover with cross bridges staying attached longer and prolonging myofibril relaxation. Danicamtiv corrected decreased calcium sensitivity in demembranated tissue, abnormal twitch magnitude and kinetics in intact cardiac tissue, and reduced ejection fraction in the whole organ. CONCLUSIONS As demonstrated by the detailed studies of Danicamtiv, increasing myosin recruitment and altering cross-bridge cycling are 2 mechanisms to increase force and calcium sensitivity in cardiac muscle. Myosin activators such as Danicamtiv can treat the causative hypocontractile phenotype in genetic dilated cardiomyopathy.
Collapse
Affiliation(s)
- Kristina B. Kooiker
- Division of Cardiology, Medicine (K.B.K., M.M.-S., J.C.F., E.G.C.A., F.M.-H.), University of Washington
- Center of Translational Muscle Research (K.B.K., S.M., G.F., T.S.M., C.M., A.-Y.T., M.R., J.D., F.M.-H.), University of Washington
- Center for Cardiovascular Biology (K.B.K., A.M., M.R., J.D., F.M.-H.), University of Washington
- Institute for Stem Cell & Regenerative Medicine (K.B.K., S.M., A.M., T.S.M., A.-Y.T., M.R., J.D., F.M.-H.), University of Washington
| | - Saffie Mohran
- Center of Translational Muscle Research (K.B.K., S.M., G.F., T.S.M., C.M., A.-Y.T., M.R., J.D., F.M.-H.), University of Washington
- Institute for Stem Cell & Regenerative Medicine (K.B.K., S.M., A.M., T.S.M., A.-Y.T., M.R., J.D., F.M.-H.), University of Washington
- Department of Bioengineering (S.M., A.M., G.F., C.M., A.-Y.T., M.R., J.D.), University of Washington
| | - Kyrah L. Turner
- School of Molecular Biosciences, Washington State University (K.L.T.)
| | - Weikang Ma
- Department of Biology, Illinois Institute of Technology, Chicago (W.M., L.Q., T.C.I.)
| | - Amy Martinson
- Center for Cardiovascular Biology (K.B.K., A.M., M.R., J.D., F.M.-H.), University of Washington
- Department of Laboratory Medicine and Pathology (A.M., J.D., F.M.-H.), University of Washington
- Institute for Stem Cell & Regenerative Medicine (K.B.K., S.M., A.M., T.S.M., A.-Y.T., M.R., J.D., F.M.-H.), University of Washington
- Department of Bioengineering (S.M., A.M., G.F., C.M., A.-Y.T., M.R., J.D.), University of Washington
| | - Galina Flint
- Center of Translational Muscle Research (K.B.K., S.M., G.F., T.S.M., C.M., A.-Y.T., M.R., J.D., F.M.-H.), University of Washington
- Department of Bioengineering (S.M., A.M., G.F., C.M., A.-Y.T., M.R., J.D.), University of Washington
| | - Lin Qi
- Department of Biology, Illinois Institute of Technology, Chicago (W.M., L.Q., T.C.I.)
| | - Chengqian Gao
- College of Basic Medical Sciences, Dalian Medical University, Liaoning, China (C.G., Y.Z.)
| | - Yahan Zheng
- College of Basic Medical Sciences, Dalian Medical University, Liaoning, China (C.G., Y.Z.)
| | - Timothy S. McMillen
- Center of Translational Muscle Research (K.B.K., S.M., G.F., T.S.M., C.M., A.-Y.T., M.R., J.D., F.M.-H.), University of Washington
- Institute for Stem Cell & Regenerative Medicine (K.B.K., S.M., A.M., T.S.M., A.-Y.T., M.R., J.D., F.M.-H.), University of Washington
- Department of Anesthesiology and Pain Medicine (T.S.M.), University of Washington
| | - Christian Mandrycky
- Center of Translational Muscle Research (K.B.K., S.M., G.F., T.S.M., C.M., A.-Y.T., M.R., J.D., F.M.-H.), University of Washington
- Department of Bioengineering (S.M., A.M., G.F., C.M., A.-Y.T., M.R., J.D.), University of Washington
| | - Max Mahoney-Schaefer
- Division of Cardiology, Medicine (K.B.K., M.M.-S., J.C.F., E.G.C.A., F.M.-H.), University of Washington
| | - Jeremy C. Freeman
- Division of Cardiology, Medicine (K.B.K., M.M.-S., J.C.F., E.G.C.A., F.M.-H.), University of Washington
| | | | - An-Yu Tu
- Center of Translational Muscle Research (K.B.K., S.M., G.F., T.S.M., C.M., A.-Y.T., M.R., J.D., F.M.-H.), University of Washington
- Institute for Stem Cell & Regenerative Medicine (K.B.K., S.M., A.M., T.S.M., A.-Y.T., M.R., J.D., F.M.-H.), University of Washington
- Department of Bioengineering (S.M., A.M., G.F., C.M., A.-Y.T., M.R., J.D.), University of Washington
| | - Thomas C. Irving
- Department of Biology, Illinois Institute of Technology, Chicago (W.M., L.Q., T.C.I.)
| | - Michael A. Geeves
- School of Biosciences, Division of Natural Sciences, University of Kent, Canterbury, United Kingdom (M.A.G.)
| | - Bertrand C.W. Tanner
- Department of Integrative Physiology and Neuroscience, Washington State University (B.C.W.T.)
| | - Michael Regnier
- Center of Translational Muscle Research (K.B.K., S.M., G.F., T.S.M., C.M., A.-Y.T., M.R., J.D., F.M.-H.), University of Washington
- Center for Cardiovascular Biology (K.B.K., A.M., M.R., J.D., F.M.-H.), University of Washington
- Institute for Stem Cell & Regenerative Medicine (K.B.K., S.M., A.M., T.S.M., A.-Y.T., M.R., J.D., F.M.-H.), University of Washington
- Department of Bioengineering (S.M., A.M., G.F., C.M., A.-Y.T., M.R., J.D.), University of Washington
| | - Jennifer Davis
- Center of Translational Muscle Research (K.B.K., S.M., G.F., T.S.M., C.M., A.-Y.T., M.R., J.D., F.M.-H.), University of Washington
- Center for Cardiovascular Biology (K.B.K., A.M., M.R., J.D., F.M.-H.), University of Washington
- Department of Laboratory Medicine and Pathology (A.M., J.D., F.M.-H.), University of Washington
- Institute for Stem Cell & Regenerative Medicine (K.B.K., S.M., A.M., T.S.M., A.-Y.T., M.R., J.D., F.M.-H.), University of Washington
- Department of Bioengineering (S.M., A.M., G.F., C.M., A.-Y.T., M.R., J.D.), University of Washington
| | - Farid Moussavi-Harami
- Division of Cardiology, Medicine (K.B.K., M.M.-S., J.C.F., E.G.C.A., F.M.-H.), University of Washington
- Center of Translational Muscle Research (K.B.K., S.M., G.F., T.S.M., C.M., A.-Y.T., M.R., J.D., F.M.-H.), University of Washington
- Center for Cardiovascular Biology (K.B.K., A.M., M.R., J.D., F.M.-H.), University of Washington
- Department of Laboratory Medicine and Pathology (A.M., J.D., F.M.-H.), University of Washington
- Institute for Stem Cell & Regenerative Medicine (K.B.K., S.M., A.M., T.S.M., A.-Y.T., M.R., J.D., F.M.-H.), University of Washington
| |
Collapse
|
5
|
Tikunova SB, Thuma J, Davis JP. Mouse Models of Cardiomyopathies Caused by Mutations in Troponin C. Int J Mol Sci 2023; 24:12349. [PMID: 37569724 PMCID: PMC10419064 DOI: 10.3390/ijms241512349] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/01/2023] [Revised: 07/27/2023] [Accepted: 08/01/2023] [Indexed: 08/13/2023] Open
Abstract
Cardiac muscle contraction is regulated via Ca2+ exchange with the hetero-trimeric troponin complex located on the thin filament. Binding of Ca2+ to cardiac troponin C, a Ca2+ sensing subunit within the troponin complex, results in a series of conformational re-arrangements among the thin filament components, leading to an increase in the formation of actomyosin cross-bridges and muscle contraction. Ultimately, a decline in intracellular Ca2+ leads to the dissociation of Ca2+ from troponin C, inhibiting cross-bridge cycling and initiating muscle relaxation. Therefore, troponin C plays a crucial role in the regulation of cardiac muscle contraction and relaxation. Naturally occurring and engineered mutations in troponin C can lead to altered interactions among components of the thin filament and to aberrant Ca2+ binding and exchange with the thin filament. Mutations in troponin C have been associated with various forms of cardiac disease, including hypertrophic, restrictive, dilated, and left ventricular noncompaction cardiomyopathies. Despite progress made to date, more information from human studies, biophysical characterizations, and animal models is required for a clearer understanding of disease drivers that lead to cardiomyopathies. The unique use of engineered cardiac troponin C with the L48Q mutation that had been thoroughly characterized and genetically introduced into mouse myocardium clearly demonstrates that Ca2+ sensitization in and of itself should not necessarily be considered a disease driver. This opens the door for small molecule and protein engineering strategies to help boost impaired systolic function. On the other hand, the engineered troponin C mutants (I61Q and D73N), genetically introduced into mouse myocardium, demonstrate that Ca2+ desensitization under basal conditions may be a driving factor for dilated cardiomyopathy. In addition to enhancing our knowledge of molecular mechanisms that trigger hypertrophy, dilation, morbidity, and mortality, these cardiomyopathy mouse models could be used to test novel treatment strategies for cardiovascular diseases. In this review, we will discuss (1) the various ways mutations in cardiac troponin C might lead to disease; (2) relevant data on mutations in cardiac troponin C linked to human disease, and (3) all currently existing mouse models containing cardiac troponin C mutations (disease-associated and engineered).
Collapse
Affiliation(s)
- Svetlana B. Tikunova
- Department of Physiology and Cell Biology, Dorothy M. Davis Heart and Lung Research Institute, College of Medicine, The Ohio State University, Columbus, OH 43210, USA (J.P.D.)
| | | | | |
Collapse
|
6
|
Prodanovic M, Wang Y, Mijailovich SM, Irving T. Using Multiscale Simulations as a Tool to Interpret Equatorial X-ray Fiber Diffraction Patterns from Skeletal Muscle. Int J Mol Sci 2023; 24:8474. [PMID: 37239821 PMCID: PMC10218096 DOI: 10.3390/ijms24108474] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/31/2023] [Revised: 05/04/2023] [Accepted: 05/05/2023] [Indexed: 05/28/2023] Open
Abstract
Synchrotron small-angle X-ray diffraction is the method of choice for nm-scale structural studies of striated muscle under physiological conditions and on millisecond time scales. The lack of generally applicable computational tools for modeling X-ray diffraction patterns from intact muscles has been a significant barrier to exploiting the full potential of this technique. Here, we report a novel "forward problem" approach using the spatially explicit computational simulation platform MUSICO to predict equatorial small-angle X-ray diffraction patterns and the force output simultaneously from resting and isometrically contracting rat skeletal muscle that can be compared to experimental data. The simulation generates families of thick-thin filament repeating units, each with their individually predicted occupancies of different populations of active and inactive myosin heads that can be used to generate 2D-projected electron density models based on known Protein Data Bank structures. We show how, by adjusting only a few selected parameters, we can achieve a good correspondence between experimental and predicted X-ray intensities. The developments presented here demonstrate the feasibility of combining X-ray diffraction and spatially explicit modeling to form a powerful hypothesis-generating tool that can be used to motivate experiments that can reveal emergent properties of muscle.
Collapse
Affiliation(s)
- Momcilo Prodanovic
- Institute for Information Technologies, University of Kragujevac, 34000 Kragujevac, Serbia;
- FilamenTech, Inc., Newton, MA 02458, USA;
| | - Yiwei Wang
- Department of Applied Mathematics, Illinois Institute of Technology, Chicago, IL 60616, USA;
- Department of Biology, Illinois Institute of Technology, Chicago, IL 60616, USA
- Department of Mathematics, University of California, Riverside, CA 92521, USA
| | | | - Thomas Irving
- Department of Biology, Illinois Institute of Technology, Chicago, IL 60616, USA
| |
Collapse
|
7
|
Asencio A, Malingen S, Kooiker KB, Powers JD, Davis J, Daniel T, Moussavi-Harami F. Machine learning meets Monte Carlo methods for models of muscle's molecular machinery to classify mutations. J Gen Physiol 2023; 155:e202213291. [PMID: 37000171 PMCID: PMC10067704 DOI: 10.1085/jgp.202213291] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/31/2022] [Revised: 02/14/2023] [Accepted: 03/14/2023] [Indexed: 04/01/2023] Open
Abstract
The timing and magnitude of force generation by a muscle depend on complex interactions in a compliant, contractile filament lattice. Perturbations in these interactions can result in cardiac muscle diseases. In this study, we address the fundamental challenge of connecting the temporal features of cardiac twitches to underlying rate constants and their perturbations associated with genetic cardiomyopathies. Current state-of-the-art metrics for characterizing the mechanical consequence of cardiac muscle disease do not utilize information embedded in the complete time course of twitch force. We pair dimension reduction techniques and machine learning methods to classify underlying perturbations that shape the timing of twitch force. To do this, we created a large twitch dataset using a spatially explicit Monte Carlo model of muscle contraction. Uniquely, we modified the rate constants of this model in line with mouse models of cardiac muscle disease and varied mutation penetrance. Ultimately, the results of this study show that machine learning models combined with biologically informed dimension reduction techniques can yield excellent classification accuracy of underlying muscle perturbations.
Collapse
Affiliation(s)
- Anthony Asencio
- Department of Biology, University of Washington, Seattle, WA, USA
- Department of Bioengineering, University of Washington, Seattle, WA, USA
- Division of Cardiology, University of Washington, Seattle, WA, USA
- Center for Transnational Muscle Research, University of Washington, Seattle, WA, USA
| | - Sage Malingen
- Department of Bioengineering, University of Washington, Seattle, WA, USA
- Center for Transnational Muscle Research, University of Washington, Seattle, WA, USA
| | - Kristina B. Kooiker
- Division of Cardiology, University of Washington, Seattle, WA, USA
- Center for Transnational Muscle Research, University of Washington, Seattle, WA, USA
- Center for Cardiovascular Biology, University of Washington, Seattle, WA, USA
| | - Joseph D. Powers
- Department of Bioengineering, University of California, San Diego, San Diego, CA, USA
| | - Jennifer Davis
- Department of Bioengineering, University of Washington, Seattle, WA, USA
- Center for Transnational Muscle Research, University of Washington, Seattle, WA, USA
- Department of Laboratory Medicine Pathology, University of Washington, Seattle, WA, USA
- Center for Cardiovascular Biology, University of Washington, Seattle, WA, USA
| | - Thomas Daniel
- Department of Biology, University of Washington, Seattle, WA, USA
- Department of Bioengineering, University of Washington, Seattle, WA, USA
- Center for Transnational Muscle Research, University of Washington, Seattle, WA, USA
| | - Farid Moussavi-Harami
- Division of Cardiology, University of Washington, Seattle, WA, USA
- Center for Transnational Muscle Research, University of Washington, Seattle, WA, USA
- Department of Laboratory Medicine Pathology, University of Washington, Seattle, WA, USA
- Center for Cardiovascular Biology, University of Washington, Seattle, WA, USA
| |
Collapse
|
8
|
Tomasevic S, Milosevic M, Milicevic B, Simic V, Prodanovic M, Mijailovich SM, Filipovic N. Computational Modeling on Drugs Effects for Left Ventricle in Cardiomyopathy Disease. Pharmaceutics 2023; 15:793. [PMID: 36986654 PMCID: PMC10058954 DOI: 10.3390/pharmaceutics15030793] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/26/2022] [Revised: 02/09/2023] [Accepted: 02/24/2023] [Indexed: 03/04/2023] Open
Abstract
Cardiomyopathy is associated with structural and functional abnormalities of the ventricular myocardium and can be classified in two major groups: hypertrophic (HCM) and dilated (DCM) cardiomyopathy. Computational modeling and drug design approaches can speed up the drug discovery and significantly reduce expenses aiming to improve the treatment of cardiomyopathy. In the SILICOFCM project, a multiscale platform is developed using coupled macro- and microsimulation through finite element (FE) modeling of fluid-structure interactions (FSI) and molecular drug interactions with the cardiac cells. FSI was used for modeling the left ventricle (LV) with a nonlinear material model of the heart wall. Simulations of the drugs' influence on the electro-mechanics LV coupling were separated in two scenarios, defined by the principal action of specific drugs. We examined the effects of Disopyramide and Dygoxin which modulate Ca2+ transients (first scenario), and Mavacamten and 2-deoxy adenosine triphosphate (dATP) which affect changes of kinetic parameters (second scenario). Changes of pressures, displacements, and velocity distributions, as well as pressure-volume (P-V) loops in the LV models of HCM and DCM patients were presented. Additionally, the results obtained from the SILICOFCM Risk Stratification Tool and PAK software for high-risk HCM patients closely followed the clinical observations. This approach can give much more information on risk prediction of cardiac disease to specific patients and better insight into estimated effects of drug therapy, leading to improved patient monitoring and treatment.
Collapse
Affiliation(s)
- Smiljana Tomasevic
- Faculty of Engineering, University of Kragujevac, 34000 Kragujevac, Serbia
- BioIRC Bioengineering Research and Development Center, 34000 Kragujevac, Serbia
| | - Miljan Milosevic
- BioIRC Bioengineering Research and Development Center, 34000 Kragujevac, Serbia
- Institute for Information Technologies, University of Kragujevac, 34000 Kragujevac, Serbia
| | - Bogdan Milicevic
- Faculty of Engineering, University of Kragujevac, 34000 Kragujevac, Serbia
- BioIRC Bioengineering Research and Development Center, 34000 Kragujevac, Serbia
| | - Vladimir Simic
- BioIRC Bioengineering Research and Development Center, 34000 Kragujevac, Serbia
- Institute for Information Technologies, University of Kragujevac, 34000 Kragujevac, Serbia
| | - Momcilo Prodanovic
- BioIRC Bioengineering Research and Development Center, 34000 Kragujevac, Serbia
- Institute for Information Technologies, University of Kragujevac, 34000 Kragujevac, Serbia
- FilamenTech, Inc., Newton, MA 02458, USA
| | - Srboljub M. Mijailovich
- FilamenTech, Inc., Newton, MA 02458, USA
- BioCAT, Department of Biology, Illinois Institute of Technology, Chicago, IL 60616, USA
| | - Nenad Filipovic
- Faculty of Engineering, University of Kragujevac, 34000 Kragujevac, Serbia
- BioIRC Bioengineering Research and Development Center, 34000 Kragujevac, Serbia
| |
Collapse
|
9
|
Kooiker KB, Mohran S, Turner KL, Ma W, Flint G, Qi L, Gao C, Zheng Y, McMillen TS, Mandrycky C, Martinson A, Mahoney-Schaefer M, Freeman JC, Costales Arenas EG, Tu AY, Irving TC, Geeves MA, Tanner BCW, Regnier M, Davis J, Moussavi-Harami F. Danicamtiv increases myosin recruitment and alters the chemomechanical cross bridge cycle in cardiac muscle. BIORXIV : THE PREPRINT SERVER FOR BIOLOGY 2023:2023.01.31.526380. [PMID: 36778318 PMCID: PMC9915609 DOI: 10.1101/2023.01.31.526380] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 02/05/2023]
Abstract
Modulating myosin function is a novel therapeutic approach in patients with cardiomyopathy. Detailed mechanism of action of these agents can help predict potential unwanted affects and identify patient populations that can benefit most from them. Danicamtiv is a novel myosin activator with promising preclinical data that is currently in clinical trials. While it is known danicamtiv increases force and cardiomyocyte contractility without affecting calcium levels, detailed mechanistic studies regarding its mode of action are lacking. Using porcine cardiac tissue and myofibrils we demonstrate that Danicamtiv increases force and calcium sensitivity via increasing the number of myosin in the "on" state and slowing cross bridge turnover. Our detailed analysis shows that inhibition of ADP release results in decreased cross bridge turnover with cross bridges staying on longer and prolonging myofibril relaxation. Using a mouse model of genetic dilated cardiomyopathy, we demonstrated that Danicamtiv corrected calcium sensitivity in demembranated and abnormal twitch magnitude and kinetics in intact cardiac tissue. Significance Statement Directly augmenting sarcomere function has potential to overcome limitations of currently used inotropic agents to improve cardiac contractility. Myosin modulation is a novel mechanism for increased contraction in cardiomyopathies. Danicamtiv is a myosin activator that is currently under investigation for use in cardiomyopathy patients. Our study is the first detailed mechanism of how Danicamtiv increases force and alters kinetics of cardiac activation and relaxation. This new understanding of the mechanism of action of Danicamtiv can be used to help identify patients that could benefit most from this treatment.
Collapse
|
10
|
Abstract
Hypertrophic cardiomyopathy (HCM), the most common inherited heart disease, is still orphan of a specific drug treatment. The erroneous consideration of HCM as a rare disease has hampered the design and conduct of large, randomized trials in the last 50 years, and most of the indications in the current guidelines are derived from small non-randomized studies, case series, or simply from the consensus of experts. Guideline-directed therapy of HCM includes non-selective drugs such as disopyramide, non-dihydropyridine calcium channel blockers, or β-adrenergic receptor blockers, mainly used in patients with symptomatic obstruction of the outflow tract. Following promising preclinical studies, several drugs acting on potential HCM-specific targets were tested in patients. Despite the huge efforts, none of these studies was able to change clinical practice for HCM patients, because tested drugs were proven to be scarcely effective or hardly tolerated in patients. However, novel compounds have been developed in recent years specifically for HCM, addressing myocardial hypercontractility and altered energetics in a direct manner, through allosteric inhibition of myosin. In this paper, we will critically review the use of different classes of drugs in HCM patients, starting from "old" established agents up to novel selective drugs that have been recently trialed in patients.
Collapse
|
11
|
Prodanovic M, Geeves MA, Poggesi C, Regnier M, Mijailovich SM. Effect of Myosin Isoforms on Cardiac Muscle Twitch of Mice, Rats and Humans. Int J Mol Sci 2022; 23:1135. [PMID: 35163054 PMCID: PMC8835009 DOI: 10.3390/ijms23031135] [Citation(s) in RCA: 9] [Impact Index Per Article: 4.5] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/09/2021] [Revised: 01/16/2022] [Accepted: 01/18/2022] [Indexed: 02/04/2023] Open
Abstract
To understand how pathology-induced changes in contractile protein isoforms modulate cardiac muscle function, it is necessary to quantify the temporal-mechanical properties of contractions that occur under various conditions. Pathological responses are much easier to study in animal model systems than in humans, but extrapolation between species presents numerous challenges. Employing computational approaches can help elucidate relationships that are difficult to test experimentally by translating the observations from rats and mice, as model organisms, to the human heart. Here, we use the spatially explicit MUSICO platform to model twitch contractions from rodent and human trabeculae collected in a single laboratory. This approach allowed us to identify the variations in kinetic characteristics of α- and β-myosin isoforms across species and to quantify their effect on cardiac muscle contractile responses. The simulations showed how the twitch transient varied with the ratio of the two myosin isoforms. Particularly, the rate of tension rise was proportional to the fraction of α-myosin present, while the β-isoform dominated the rate of relaxation unless α-myosin was >50%. Moreover, both the myosin isoform and the Ca2+ transient contributed to the twitch tension transient, allowing two levels of regulation of twitch contraction.
Collapse
Affiliation(s)
- Momcilo Prodanovic
- Institute for Information Technologies, University of Kragujevac, 34000 Kragujevac, Serbia;
- Bioengineering Research and Development Center (BioIRC), 34000 Kragujevac, Serbia
- FilamenTech, Inc., Newtown, MA 02458, USA
| | - Michael A. Geeves
- Department of Biosciences, University of Kent, Canterbury CT2 7NJ, Kent, UK;
| | - Corrado Poggesi
- Department of Experimental & Clinical Medicine, University of Florence, 20134 Florence, Italy;
| | - Michael Regnier
- Department of Bioengineering, University of Washington, Seattle, WA 98105, USA;
| | - Srboljub M. Mijailovich
- FilamenTech, Inc., Newtown, MA 02458, USA
- Department of Biology, Illinois Institute of Technology, Chicago, IL 60616, USA
| |
Collapse
|
12
|
Ion Channel Impairment and Myofilament Ca 2+ Sensitization: Two Parallel Mechanisms Underlying Arrhythmogenesis in Hypertrophic Cardiomyopathy. Cells 2021; 10:cells10102789. [PMID: 34685769 PMCID: PMC8534456 DOI: 10.3390/cells10102789] [Citation(s) in RCA: 10] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/15/2021] [Revised: 10/07/2021] [Accepted: 10/13/2021] [Indexed: 11/17/2022] Open
Abstract
Life-threatening ventricular arrhythmias are the main clinical burden in patients with hypertrophic cardiomyopathy (HCM), and frequently occur in young patients with mild structural disease. While massive hypertrophy, fibrosis and microvascular ischemia are the main mechanisms underlying sustained reentry-based ventricular arrhythmias in advanced HCM, cardiomyocyte-based functional arrhythmogenic mechanisms are likely prevalent at earlier stages of the disease. In this review, we will describe studies conducted in human surgical samples from HCM patients, transgenic animal models and human cultured cell lines derived from induced pluripotent stem cells. Current pieces of evidence concur to attribute the increased risk of ventricular arrhythmias in early HCM to different cellular mechanisms. The increase of late sodium current and L-type calcium current is an early observation in HCM, which follows post-translation channel modifications and increases the occurrence of early and delayed afterdepolarizations. Increased myofilament Ca2+ sensitivity, commonly observed in HCM, may promote afterdepolarizations and reentry arrhythmias with direct mechanisms. Decrease of K+-currents due to transcriptional regulation occurs in the advanced disease and contributes to reducing the repolarization-reserve and increasing the early afterdepolarizations (EADs). The presented evidence supports the idea that patients with early-stage HCM should be considered and managed as subjects with an acquired channelopathy rather than with a structural cardiac disease.
Collapse
|